A diversity of immune tolerance mechanisms have evolved to protect normal tissues from immune damage. Immune regulatory cells are critical contributors to peripheral tolerance. These regulatory cells, exemplified by the CD4 + Foxp3 + regulatory T (Treg) cells and a recently identified population named myeloid-derived suppressor cells (MDSCs), regulate immune responses and limiting immune-mediated pathology. In a chronic inflammatory setting, such as allograft-directed immunity, there may be a dynamic "cross-talk" between the innate and adaptive immunomodulatory mechanisms for an integrated control of immune damage. CTLA4-B7-based interaction between the two branches may function as a molecular "bridge" to facilitate such "cross-talk." Understanding the interplays among Treg cells, innate suppressors, and pathogenic effector T (Teff) cells will be critical in the future to assist in the development of therapeutic strategies to enhance and synergize physiological immunosuppressive elements in the innate and adaptive immune system. Successful development of localized strategies of regulatory cell therapies could circumvent the requirement for very high number of cells and decrease the risks associated with systemic immunosuppression. To realize the potential of innate and adaptive immune regulators for the still elusive goal of immune tolerance induction, adoptive cell therapies may also need to be coupled with agents enhancing endogenous tolerance mechanisms. 253 254 SUZUKI, RICORDI, AND CHEN
INTRODUCTION
erance has dominated several decades of immune tolerance research with the objective to control alloimmunity and/or autoimmunity. Multicellular organisms are equipped with an innate immune system that recognizes objects with a pattern A variety of tolerance mechanisms have been discovered to be responsible for protection of the body's own distinct from their own tissues. Vertebrates have also evolved an adaptive immune system to fend off infec-tissue from immune injuries while effectively fighting pathogens. For T lymphocytes, these mechanisms in-tious agents with a fine specificity. Cell and organ transplants from genetically nonidentical donors are rec-clude central tolerance (thymic deletion of autoreactive T cells). In transplantation, central tolerance may have ognized for their allogeneic "foreign" antigens by the host's immune system and rejected if antigraft immune contributed to the success of selected tolerance induction strategies aiming at the establishment of donor bone responses are not prevented or subdued. Since Medawar and colleagues demonstrated in 1953 that some mice marrow chimerism (131) . A critical mechanism of peripheral tolerance is dominant suppression by the Foxp3 + treated with allogeneic cells at neonatal age tolerated skin allografts later (10) , the hope for development of regulatory T (Treg) cells (101) , which is regarded with extraordinary potential by immune tolerance strategies. successful strategies for achieving acquired immune tol-Nonetheless, a complex and synergistic interaction of function, such as insulin production in T1DM, but immune rejection of transplants has been a major hurdle. several tolerance induction mechanisms may be required to prevent autoimmune damage in a normal individual Potent immunosuppressive drugs are required to suppress rejection of the grafts. The indiscriminative immunosup- (20) , and may also be required for the induction of tolerance to transplanted organs, tissues, or cells.
pression often causes serious and sometimes life-threatening side effects. It remains a goal to induce immune THE CD4 + Foxp3 + Treg CELL: tolerance to transplants, so patients with transplants can A KEY SUPPRESSOR IN THE achieve permanent acceptance of grafts in the absence ADAPTIVE IMMUNE SYSTEM of life-long immunosuppressive drugs. The discovery of Lymphocytes are the major effectors of adaptive im-Treg cells opens an exciting new venue for immune conmunity. Immunosuppression by lymphocytes, however, trol of transplant rejection (138). Transplantation, on the had remained an elusive and controversial phenomenon other hand, offers one of the most appealing platforms until Sakaguchi and Powrie independently identified infor a Treg cell therapy trial for two reasons: 1) T lymhibitory subsets of murine T cells expressing CD25 (100) phocytes play a major role in allotransplant rejection, or having a lower level of CD45RB (92). These two and 2) Treg cell therapy may be timed precisely to cermurine phenotypes overlap in a subset of CD4 + CD25 + tain stages of graft rejection responses and the stages regulatory T cells that were later found by several studcan be clinically managed with timing of surgery and a ies to have a definitive marker, the Foxp3 transcription battery of immunosuppressive agents. factor (101) . Immunosuppressive activities have also Preclinical studies with animal models of allotransbeen found in other lymphocyte subsets, including NK plantation have indeed provided clear evidence to justify cells, NK T cells, and B lymphocytes. Suppressive inadoptive Treg cell therapies in clinical trials. Some trials flammatory cytokines, such as IL-10, can induce suphave already begun (97, 98) . The preclinical efficacy of pressive T cells without implicating Foxp3 expression, Treg cell therapy in transplantation experiments so far, of which the Tr1 cell is a well-known example (48) .
however, has been limited to graft recipients with These various subsets of suppressive lymphocytes could lymphopenic conditions, such as following irradiation or play an important role within different contexts of inlymphodepletion treatments. It remains to be shown flammatory settings. Extensive studies have established whether Treg cell therapies can be effective in transplan-Foxp3 + Treg cells as a key subset of regulatory cells that tation settings in which the hosts are fully immunocommaintain homeostasis of the immune system, preventing petent. Conceivably, Treg cell therapy would be difficult the development of autoimmune responses. Lack of the to succeed in such settings due to lack of "space" in a Foxp3 gene causes a human autoimmune disorder, the fully competent immune system, which could make it Immunodysregulation, Polyendocrinopathy, Enteropathy, challenging for adoptively transferred Treg cells to en-X linked (IPEX) Syndrome, characterized by chronic digraft and persist. However, host conditioning strategies arrhea, type 1 diabetes mellitus (T1DM), and inflammathat result in lymphopenia are well developed in the contory damages to other organs in early childhood (135) .
text of hematopoietic stem cell transplantation (HSCT) Mice with a null mutation of the Foxp3 gene have masfrom allogeneic donors. In clinical HSCT, alloimmune sive lymphoproliferation and severe inflammatory infilresponses of donor-derived T cells against recipient tistration of the skin, liver, and lung. Acute ablation of sues cause graft-versus-host disease (GVHD), which is Treg cells in adult animals induced lethal autoimmune a major cause of morbidity and mortality. The protective disorders (61) . In a mouse model T1DM, absence of role of Treg cells against GVHD was reported by Taylor Foxp3 led to fulminant autoimmune destruction of panet al. (118) and subsequently confirmed by others (97, creatic islet β-cells in very young animals that would 98). The field of prevention and treatment of GVHD have otherwise been protected from diabetes for their provides perhaps the most convincing evidence for Treg life time (21). Evidence from extensive studies in the cell-based control of alloimmunity. Indeed, a pioneering last decade has indicated that Treg cells have perhaps clinical trial of Treg cell therapy in HSCT (97) is in the most versatile suppressive function among immunoprogress with great anticipation for its possible implicaregulatory cells identified so far. The robust suppressive tions for several immune-mediated conditions.
activity of Treg cells in various preclinical tests has led
Even if lymphopenia is a requirement for engraftment to an extraordinary expectation of Treg cell therapies for of adoptive Treg cells, such therapy may still be applicaa variety of human immune disorders (e.g., T1DM and ble to the broader field of transplantation. Transient lymtransplantations).
phopenia is an integral part of posttransplant physiopath-Treg Cells in Transplantation ological condition in several clinical settings besides HSCT. Lymphodepleting agents, such as ATG, anti-CD20 Transplantation is a vital remedy in cases of organ failure or for the replacement of a defective physiologic antibodies and Campath 1-H (anti-CD52 antibodies), are increasingly used. Lymphopenia is even observed and tients. Perhaps, a valuable lesson learned from the NOD model of T1DM is the diversity of immunological considered a requirement for success of immunosuppressive strategies in transplant recipients treated with mechanisms that is required to enforce tolerance of pancreatic β-cells. Besides the intrinsic "unruliness" of the agents that are not specifically designed for a primary lymphodepleting effect, such as the combination of ra-pathogenic Teff cells, studies have demonstrated a flawed central tolerance as a root cause of the autoim-pamycin, FK506, and anti-IL2R antibodies (Edmonton Protocol) in islet transplant recipients (79).
mune diabetes in this model (75) . Defective central tolerance may not be readily amenable with adoptive Treg Treg Cells in T1DM cell therapies (75) . In addition, alteration of innate immune cells may also contribute to the breakdown of im-T1DM, also called insulin-dependent diabetes mellitus (IDDM), is mainly caused by T-cell-mediated, spon-mune tolerance in the NOD models, as suggested by many studies. Thus, a more effective outcome of im-taneous autoimmune destruction of the insulin-producing β-cells in pancreatic islets. The critical features of mune tolerance therapy for T1DM may require a strategy that integrates the various tolerogenic elements in IDDM in humans, especially the immunological aspects, are closely mimicked by the spontaneous diabetes in a the immune system. murine model, the nonobese diabetic (NOD) mouse. Im-MDSCs AS INNATE IMMUNOMODULATORS munological research in T1DM has served as a flagship for the field of immune tolerance induction. Indeed, the Cells derived from myeloid hematopoiesis, including granulocytes, monocytes (macrophages, MΦ), and den-discovery of Treg cells has led to an intensive focus on their preventive and therapeutic potentials for T1DM. dritic cells (DCs) are critical constituents of the innate immune system. Tumor immunologists have long dis-The protective role of naturally occurring Foxp3 + Treg (nTreg) cells has been unequivocally established in ani-covered the phenomenon of immunosuppression by cells from myeloid origins. Among the pioneers are Lopez mal models of T1DM by many independent studies (107). T1DM is a major manifestation of IPEX, indicat-and colleagues, who discovered suppressive activity of macrophages in tumor bearing animals (37) . Suppressive ing that a lack of Treg cells causes a high probability of diabetes (135) . However, IPEX cases are very rare. Most macrophages were also identified in human cancer tissues (62). Their immunosuppressive function was shown T1DM patients do not have a loss-of-function mutation in the Foxp3 gene. Actually, characterization with the to be mediated, at least partially, by B7-H4. B7-H4 is a recently discovered member in the costimulatory family Foxp3 marker for Treg cells refuted an earlier notion that there was a readily detectable Treg cell deficit in but functions as an inhibitory molecule suppressing immune responses. It plays a distinct role in modulating the general population of T1DM (16) . In addition, there is no association of T1DM incidence with genetic poly-both adaptive and innate immunity (142) . A novel agent, human B7-H4-Ig fusion protein, showed potential in morphisms at the Foxp3 locus in the general population (11) . The upshot that Treg cells in most T1DM patients suppressing in vitro responses of human T cells to βcell antigens (88) . appear normal conveys a piece of mixed news. On one hand, the patient's own Treg cells, after in vitro expan-DCs, well known for their capacity to elicit immunity, also play a substantial role in the physiological sion (70, 93) , should serve competently for potential therapeutic use; on the other hand, it raises doubt on the process of immune tolerance induction. DCs refer to a heterogeneous population of professional antigen-rationale for infusing more Treg cells into the patients if they do not have Treg cell deficit to begin with. presenting cells (APCs) derived from bone marrow (113). The "two-signal" hypothesis states that lympho-Adding to the complexity, recent studies with peripheral blood samples of T1DM patients showed that the cyte activation requires not only APCs to present antigen-specific signal T cells, but also proper quantity and deficit of Treg-mediated in vitro immune suppression did not reside in Treg cells per se, but rather was due to quality of costimulatory signals (13, 68) . The expression of costimulatory molecules by DCs is tightly controlled, resistance of pathogenic effector T (Teff) cells from T1DM patients to Treg cell-mediated suppression (65, with immature DCs lacking sufficient costimulatory molecules serving to enforce immune tolerance under a 103). These findings from in vitro human cell studies are consistent with in vitro and in vivo studies using physiological steady state. Inflammatory signals elicited by infections or injuries cause maturation of DCs with a the NOD mouse model of T1DM (26). In other words, although a clinical trial of Treg cell therapies for T1DM high-level expression of costimulatory molecules and thus can elicit immunity. Some members of the costimu-may well be encouraged by robust evidence from preclinical studies and logistic advances in expansion of latory family negatively regulate T-cell responses and are called coinhibitors. An unbalanced presentation of Treg cells in vitro, Treg cell therapies alone may not meet the expectation of a "wonder cure" for most pa-coinhibitory signals by DCs could also lead to suppres-sion of adverse immune responses such as that in trans-nine, so T cells in the vicinity would be "starved" and thus suppressed. Alternatively, activated MDSCs may plant rejection (124). Thus, DCs uploaded with specific antigens can be manipulated to be immunogenic to fight produce inducible nitric oxide synthase (iNOS) and reactive oxygen species (ROS) to inhibited T-cell signal-cancer and infectious agents, or tolerogenic to specifically turn off transplant immunity and autoimmunity ing (39, 87) . Although the spleen is the peripheral site in which MDSCs abound in tumor-bearing mice, the cells (43, 80, 112) . Although a tolerogenic DC (tDC) is not specific to a DC subset nor restricted to the immature accumulate at the nonlymphoid sites of inflammation as well. For example, Ilkovitch and Lopez (55) recently state of the cell, immature or maturation-resistant DCs are more likely to be tolerogenic (80). Indeed, in vitro-discovered that MDSCs accumulated in the liver to an extent comparable to the spleen in tumor-bearing mice derived immature DCs with low expression of B7 costimulatory molecules protected allogeneic heart transplants models, regardless of the existence of a metastatic tumor in the liver. The accumulation may be contributed by in mice (36) . The graft-protecting effect could be mediated by tDCs from host (40) or donor origins (71) . Cell local hematopoiesis in the liver that was driven by inflammatory signals. This observation may have a partic-therapies with tDCs remain an appealing concept, particularly with its potential to propagate other tolerogenic ular bearing to islet transplantation, as the liver is the current site of choice for clinical islet transplantation, elements in the adaptive and innate immune system (80). However, a robust protocol to control DC generation, and it has been shown as a site where tDCs and other elements may reside to render it conducive to tolerance proliferation, and differentiation remains to be developed, likely awaiting a better understanding of the DC induction (23,143). Evidence for a role of MDSCs in transplant tolerance biology (42) . The risk of terminal differentiation of immature DC into mature DC and thus exacerbating trans-is being gathered in different animal models of transplantation. Zhang et al. (144) reported that in immuno-plant rejection and autoimmunity may also be a substantial issue, especially in patients at the peritransplantation globulin-like transcript-2 (ILT-2) transgenic mice, MDSCs expanded and their suppressive activity were enhanced. period with surgery-induced milieu of inflammatory signals.
The (38), un-and accumulated in the tolerized kidney allograft. Inhibition of iNOS broke the established tolerance and led dergo massive expansion. The immunosuppressive function of MDSCs is best characterized in tumor-bearing to graft rejection (28) . In these transplantation studies (28, 144) , activated MDSCs were found in peripheral animals. Evidence also exists for their function in human patients with cancer (39, 87) . Unlike Treg cells, which blood as well as at the transplant site, indicating a potential involvement of the cells in both systemic and local can be defined by Foxp3 expression (in mice), MDSCs are not a defined cellular lineage/subset, but instead an immune tolerance, perhaps in response to stages of transplant immunity and progression of tolerance induc-inflammation-induced collection of heterogeneous immature myeloid cells with common markers and immu-tion. nosuppressive activity. Nonetheless, evidence for the CTLA4-B7 MOLECULAR INTERACTION suppressive function of MDSCs in a number of inflam-IN A "CROSS-TALK" BETWEEN matory settings (39, 87) does suggest that they may con-ADAPTIVE IMMUNOREGULATORS AND stitute a type of myeloid regulatory cell or innate sup-INNATE IMMUNOSUPPRESSORS pressor.
CD11b + Gr1 + myeloid cells represent a major popula-A Critical Role for CTLA4 in Immune Tolerance tion in the bone marrow, reflecting a continuous physiological process of myelopoiesis. They normally develop How exactly Treg cells exert their function in vivo remains a question, but clues come from characteristic into mature myeloid cells, including granulocytes, macrophages, and DCs. Under chronic inflammatory set-molecules expressed by these cells. Among the suggestive markers is CTLA4, a member of CD28/B7 costim-tings such as in tumor-bearing hosts, the cells with these immature phenotypes accumulate abnormally in the pe-ulatory family, which is expressed by Treg cells constitutively (94, 102, 114) . Mice lacking CTLA4 exhibit riphery including in the spleen and peripheral blood. Furthermore, the chronic inflammatory signals also acti-devastating lymphoproliferative disorders, multiorgan inflammatory damage, and lethality at early ages, un-vate these cells to produce arginase 1 to deplete argi-equivocally establishing CTLA4 as an inhibitory recep-deficient mice are apparently healthy, although IDO2 compensation is possible (77) . tor for T lymphocytes (120) . Very recently, Sakaguchi and colleagues reported that Treg-specific CTLA4-defi-During the last few years, with the advanced technologies of imaging, it has been discovered that lymphocyte cient mice exhibited systemic lymphoproliferation, definitively establishing a role of CTLA4 in Treg cells motility is a key element of immune responses. T cells are highly motile in steady-state physiology, but upon (136) . However, CTLA4 expression by both Treg cells and Teff cells is apparently required for its full inhibi-encountering with APC presenting specific antigens, T cells stop and engage with the APCs, which leads to T-tory function (35, 89) .
cell proliferation and differentiation (41) . Thus, regula-Molecular Models for CTLA4-Based Immunoregulation tion of the T-cell motility would serve as a "global" cellular control. Schneider et al. (104) found that CTLA4 Robust experimental evidence indicates that CTLA4 is not involved in central tolerance in the thymus (17, might reverse the antigen-induced T cell "arrest" and promoted T-cell motility, by ex vivo imaging of explan-133). On the other hand, CTLA4 has been demonstrated to play a critical role in peripheral regulation of T lym-ted lymph nodes maintained in oxygenated medium. The physiological relevance of the observations needs to be phocytes through a variety of cellular and molecular mechanisms. First, CTLA4 is rapidly upregulated on validated by noninvasive intravital imaging. However, the motility regulation model of CTLA4 function may Teff cells upon antigen stimulation through the specific T-cell receptor (TCR) and counters CD28-mediated pos-offer a plausible explanation for a role of CTLA4 in regulating immune cell interaction in lymphoid and non-itive costimulatory signals. This direct modulation of Teff cell activation is achieved through two mechanisms lymphoid target tissues. It also suggests T-cell motility control as a new venue of CTLA4-based immunotherapy that are not mutually exclusive. One mechanism is to competitively sequester B7 ligands from CD28, because for immune-mediated diseases. CTLA4 has a much higher affinity for B7 than CD28.
The Quantitative Variations of CTLA4 Expression Engaging CTLA4 on Teff cells may also deliver an Are Associated With Making or Breaking of Immune inhibitory signaling through the cytoplasmic tail of Tolerance in Humans CTLA4. CTLA4 likely functions through both pathways because: the lymphoproliferation and inflammation de-Although the CTLA4 o/o animal model served in many studies to address key questions in immunoregulation, struction in mice can be curtailed by transgenic expression of either truncated CTLA4 without cytoplasmic do-the relevance of this model to human diseases is unclear.
There is no report of complete loss of CTLA4 in hu-mains (73) or mutated CTLA4 incapable of B7 binding (24); protein transduction with CTLA4 cytoplasmic do-mans. Genetic studies have linked the CTLA4 locus to specific human autoimmune diseases, including T1DM main inhibited experimental allergic asthma (25) ; and CTLA4 blockade accelerated rejection of allografts in (119) , rather than a lymphoproliferative disorder characteristic of the CTLA4 o/o mice. No variation in the re-CD28-deficient animals (67) . Second, constitutive expression of CTLA4 by Treg cells suggests an important gions coding for CTLA4 mature proteins has been implicated, but several polymorphisms in the promoter or role of CTLA4 in Treg cell function. After much controversy in this crucial aspect of immune regulation, an 3′-untranslated region (UTR) have been identified to affect promoter efficacy for CTLA4 expression (2,5,66,132) essential role for CTLA4 in Treg cells was definitively characterized recently (136) . Third, CTLA4, expressed and/or the ratio of alternatively spliced forms of CTLA4 mRNA (127) . In animal models, some studies found that by Treg or activated Teff cells, interacts with B7 molecules on APCs to induce expression of indoleamine 2,3-autoimmunity-susceptible NOD mice expressed a lower level of full-length CTLA4 mRNA (72), whereas an-dioxygenase (IDO) in APCs and render the APCs tolerogenic (30) .
other study linked NOD mice to a modest decrease in expression of a CTLA4 splice variant (127) . What is Cellular "Motility" Model for striking from these studies is that even a modest reduc-CTLA4-Mediated Immunoregulation tion of CTLA4 expression predisposes loss of immune tolerance. Apparently, none of the aforementioned molecular models can explain the full function of CTLA4. First,
In clinical transplantation, polymorphisms of the CTLA4 locus were linked with GVHDs and acceptance overexpression of CTLA4 extracellular domain or signaling motif can only partially rescue the CTLA4 defi-of allotransplants (4, 46, 90, 137) , although conclusive evidence from a larger size of samples is still lacking. In-ciency in animals. Second, despite the intricate overlap of function between CTLA4 and Treg cells, it has been creased frequencies of transplant rejection were associated with a polymorphism at the promoter region of the demonstrated that CTLA4 and Treg cells have also distinct roles in immune tolerance (29, 54) . Third, IDO-gene (−318C) that dictates only a modest reduction of CTLA4 expression (46, 66, 132, 137) , suggesting that a the destructive activity of pathogenic T-cell responses (Fig. 1) . subtle quantitative variation of CTLA4 may reset the threshold for transplant tolerance or rejection.
CHALLENGES OF IMMUNOREGULATORY To assess the impact of a modest reduction in CTLA4 CELL THERAPIES expression on immunoregulation, a transgenic mouse model with CTLA4 RNAi has been established (22). In
In the past decade, Treg cells have attracted persistent and extensive efforts of most immunologists. Yet, an this model, the expression of CTLA4 is reduced two-to threefold in both Treg cells and activated T cells. Unlike efficacy of Treg cell therapies in clinical trials still awaits to be documented, reflecting the daunting tasks CTLA4 o/o mice, which exhibit indiscriminate multiorgan inflammatory infiltrations, CTLA4 RNAi knockdown to bring this promising therapy to benefit patients. The logistic and scientific challenges facing clinical tests of (KD) animals exhibited MHC-dependent and sitespecific autoimmune damage of the pancreatic islet in Treg cell therapies are well explained in a recent review by Riley et al. (97) . Among all difficulties and uncer-the absence of global perturbation of the immune system (22), indicating that, indeed, a modest reduction of tainties, the requirement of antigen-specificity of Treg cells may pose the most compounding factor. CTLA4 signals can have a profound but specific impact on immune tolerance.
In murine models of T1DM, β-cell-specific Treg cells are far more effective in controlling autoimmune dam-The Quantitative Signals From CTLA4 Might Serve as age than nonspecific polyclonal cells (115, 117) . In a a Molecular "Bridge" to Facilitate "Cross-Talk" mouse model of fulminant autoimmune diabetes caused Between Innate and Adaptive Immunoregulators in by genetic mutation of the Foxp3 gene, only the β-cell-Inflammatory Settings specific Treg cells, but not the nonspecific cells, could successfully reconstitute the regulatory control of diabe-It remains to be studied how a modest variation of CTLA4 levels profoundly impacts immune tolerance in-tes development (21). Proof-of-principle preclinical studies have been conducted to enrich and amplify β-cellduction. Presumably, evolution has shaped immune tolerance mechanisms into a system that integrates both the specific Treg cells (74, 116) , but successful expansion of human β-cell-specific Treg cells has yet to be docu-innate and adaptive branches. CTLA4 is constitutively expressed by Treg cells at high levels. It is further mented. If it indeed takes "a billion" (97) antigen-specific Treg cells to elicit a protective efficacy in T1DM upregulated in the damage-controlling phase of a T1DM model in pancreatic target tissue (21). The B7 ligands trials, it might take an extended period of time and effort to realize a substantial impact by this therapy in clinics. of CTLA4, particularly B7.1 (CD80), can be expressed by cells in the innate immune system including tDCs
In transplantation, the superiority of alloantigen-specific T cells has also been well documented (44,56,125). (80) and suppressive macrophages (62). MDSCs also express B7.1 (81, 110, 141) . The MDSC-mediated sup-On the other hand, antigen specificity may not be an absolute requirement (123). The efficacy of nonspecific pression of antitumor T-cell responses depended on CTLA4-B7 interaction (141) . Crystallography structural Treg cells in a transplantation setting may be due to the potential of the transferred Treg cells in suppressing the analysis of CTLA4-B7 interaction revealed that CTLA4 homodimers and alternating B7.1 homodimers can form homeostatic proliferation of pathogenic alloreactive Teff cells. Although lymphodepleting agents have been used a 'zipper"-like structure (111) . This interaction may serve to directly bridge T cells and tolerogenic innate successfully to suppress acute rejection of allografts and promote grafts from alloimmune damage, lymphopenia immune cells expressing B7.1. On the other hand, because CTLA4 and B7 can transmit intracellular signals, created by immunodepleting agents is followed with homeostatic proliferation of the residual Teff cells and CTLA4-B7-based interaction between T cells and the innate suppressors can trigger a circuitry of gene expres-heightened memory T-cell formation. In animal models, lymphopenia-driven homeostatic proliferation has been sion regulation among the regulatory cells. Taken together, the evidence suggests an integrative model of shown to present a formidable obstacle for immune tolerance induction (139) . In human patients, the transient innate and adaptive immune regulation. Quantitative CTLA4 signals may regulate interactions between Treg lymphopenia caused by immunosuppression in the Edmonton Protocol was attributed to homeostatic expan-cells and innate suppressor cells, by impacting, not mutually exclusive, the signal strength of potential regula-sion of autoreactive memory T cells that was believed to play a critical role in rejecting islet grafts in patients tory "loops" for innate and adaptive immune molecules, or the strength of an intercellular CTLA4-B7 "zipper" (79). Treg cells can efficiently modulate the pace and amplitude of lymphopenia-driven homeostatic prolifera-between the adaptive and innate regulatory cells. The CTLA4-B7-mediated integration of innate and adaptive tion in a manner that is apparently not limited by antigen specificity (3,6). Thus, a therapy with nonspecific Treg immunosuppressors can facilitate an effective control of Figure 1 . Bridging adaptive and innate immune regulators by CTLA4 and B7 molecules at inflammatory sites. Illustrated are potential interplays between immune regulatory cells and pathogenic T cells, at inflammatory sites exemplified by pancreatic islets either undergoing autoimmune attack at the onset of type 1 diabetes mellitus, or becoming the target of graft-directed immunity following islet transplantation. CTLA4-B7 interaction could function as a molecular "zipper" between Treg cells and innate suppressors, or impact a signaling "loop" of gene expression that regulates the "cross-talk" between the innate and adaptive immunoregulators. CTLA4 is constitutively expressed by Treg cells at high levels but also expressed on Teff cells upon activation. The schematic drawing is oversimplified, omitting well-characterized elements that are beyond the scope of the review. Treg, regulatory T cells; Teff, effector T cells; tDC, tolerogenic dendritic cell; MDSC, myeloid-derived suppressor cell; Supp MΦ, suppressive macrophage. Two-way arrows indicate a potential "cross-talk" between the innate and adaptive suppressor cells. An integrated immune regulatory network "brakes" pathogenic activity of Teff cells. cells may still benefit graft survival by modulating ho-cells to further differentiate to mature myeloid cells, which may mediate immune destruction, makes it a meostatic proliferation and activation of Teff cells in transplant recipients. The peritransplantation lympho-challenge to study their suppressive role in vivo, and poses a potential risk in its clinical translation. penic conditioning should also facilitate engraftment of the adoptive Treg cells, providing that the Treg cell ther-A LOCAL SOLUTION: IMMUNE TOLERANCE apies are administered in conjunction with a regimen INDUCTION AT THE TRANSPLANT SITE that is not deleterious to the transferred cells or at a time window when lymphodepleting agents are cleared from Regulated Unfolding of T1DM Highlighting the circulation and homeostatic recovery of the host T cells Potency of Local Immunoregulation has yet to begin.
As for MDSCs, rigorous efforts are devoted by many T1DM exhibits a protracted course of development. In humans, autoantibodies against islet antigens, evi-groups to examine their potential for clinical translations. The cells may be generated in vitro by culture of dence of autoreactivity against β-cells, can precede diagnosis of clinical diabetes by years. In NOD mice, insuli-bone marrow cells with a cocktail of cytokines. However, MDSC therapies will probably be more challeng-tis begins to develop in the animal at about 4 weeks after birth, but inflammatory pathology can be kept un-ing to materialize in clinical trials than Treg cell therapies. Aside from the relative early stage of knowledge der control and diabetes is not evident until ϳ12 weeks of age. To track pathogenic T cells during diabetes de-in MDSC biology compared to that of Treg cells, myeloid cells are notoriously "fragile" to in vitro process-velopment, several lines of T-cell receptor (TCR) transgenic models have been developed, among which is the ing. In addition, a large number of the cells or more frequent dosing will likely be needed because unlike BDC2.5 TCR transgenic line. This line expresses the TCR of a diabetogenic CD4 + , Th1-like, T-cell clone lymphocytes, myeloid cells are believed to have a short life span and have no capability of homeostatic expan- (51, 58) that recognizes an unknown islet antigen presented by the NOD MHC class II molecule, A g7 , but the sion upon transfer to a new host. The potential of the islet antigen itself is shared by all different strains of tolerance in the target tissue of immune damage, and suggests venues of local immunomodulation at the im-mice tested (52) . In BDC2.5/NOD mice, massive insulitis begins sharply around 2 weeks of age in all mice, mune action site. Immunotherapeutic agents are often administered in a way that results in systemic distribu-immediately after the activation of the islet-specific T cells in the pancreatic draining lymph nodes (PLN) (58) . tion in the body, but immunomodulation does not have to be systemic. One routine example in medicine is the The development of overt diabetes, however, is not accelerated but suppressed in BDC2.5/NOD mice; most topical application of anti-inflammatory agents to treat skin diseases. Local immunosuppression can efficiently animals never develop full-blown diabetes even with rampant inflammation present in the pancreatic islets deliver the agents with a much lower dose and effectively circumvent systemic side effects of the drugs. In- (45) . The diabetogenic T cells in these animals, despite their invasion in high numbers into the pancreas, are deed, promising leads of local immunosuppression have been reported in some experimental transplantation set-kept in check and a sufficient number of β-cells remain to keep the animals free of diabetes.
tings (49) . However, local delivery and retention of immunomo-Studies with a genetic model of Treg cell deficit (21) established an identity of regulatory cells in the BDC2.5 dulatory agents are difficult to achieve in most transplantation settings, including islet transplantation. Cur-models. Foxp3-deficient BDC2.5 mice are devoid of CD4 + CD25 + Treg cells, and develop diabetes with 100% rently clinical islet transplantation is performed by infusion of purified donor islets into the liver through penetrance at a "juvenile" age (by 20 days). Treating these animals with even a small number of islet-specific the portal vein. There are increasing concerns that the liver might represent a less than optimal environment CD4 + CD25 + T cells substantially inhibits diabetes development, whereas nonspecific CD4 + CD25 + T cells are not for islets. Factors associated with liver physiology and metabolism may have contributed to the progressive loss effective. In this genetic model of Treg cell function, Treg cells did not inhibit the initial activation, prolifera-of islet transplants. The physiological role of the liver as a portal to the systemic circulation also makes it difficult tion, and Th1 subset differentiation in the PLN, nor did they delay the onset of T cell infiltration of pancreatic to limit systemic distribution for agents applied to the liver. To tackle the limitations of intraportal infusion of islets. It appeared that Treg cells enforced protection of pancreatic islets by suppressing aggression of patho-islets in current clinical islet transplantation, alternative anatomical sites are explored for islet transplantation genic cells in the pancreas, halting progression from insulitis to overt diabetes (21).
(128). Neosites are also created by bioengineering approaches. A biohybrid (BHD) device has shown promise Action of Treg Cells Local at the Transplantation Sites in animal models to create an alternative, easy-to-access and Tumor Tissues site of islet transplantation (91) . The novel transplanta-There is strong evidence that Treg cells act in the tion site engineered with the BHD device was shown to transplant target tissue (121) . For example, regraft exsustain a long-term survival and function of islet transperiments demonstrated that Treg cells from tolerated plants (91) . Because the site can support the complex skin grafts transferred dominant tolerance into new rephysiology of β-cells, it is reasonable to expect that such cipients (47) . In kidney transplantation in nonhuman pria site will also be compatible with the survival and funcmates, presence of Treg cells in the inflammatory intion of Treg cells and innate suppressors. This platform filtrates of allografts correlated with graft acceptance may also be substantially improved in combination with (122) . Conversely, preventing intragraft accumulation of tissue engineering approaches such as scaffolding, nano-Treg cells correlated with rejection of cardiac allografts particle coating, and pegylation (34, 86, 134) . The sucprecipitated by toll-like receptor stimulation (19) . A recess of such a bioengineering platform would create a cent study by Shapiro's group found that the intragraft defined niche for local therapies with immunoregulatory immunopathological balance established in tolerized iscells. let grafts enabled the grafts to resist allorejection when Local therapies could circumvent the risk of general retransplanted into a new host (83) . Treg cells are also immune suppression associated with systemic infusion present in lymphocytes infiltrating tumors, where they of a large number of Treg cells (97) . Importantly, it may were thought to dampen the immune destruction of tusubstantially reduce the number of cells required for a mor cells at the microenvironment of tumor tissues therapeutic effect. In addition, it might by-pass or miti-(145).
gate the requirement of antigen specificities of Treg A "Local" Approach to Achieve Immune Tolerance cells. One reason that antigen-specific Treg cells work With a Bioengineered Platform far more efficiently may be due to effective recruitment of Treg cells to the local site of inflammatory damage. The potency of Treg cells in local protection of pancreatic islets (21) illustrates a concept of local immune This premise would suppose that local delivery of acti-vated Treg cells can suppress immune damage regard-combination with Treg cell therapies, although the direct cytotoxicity of rapamycin to transplants (e.g., to β-cells less of antigen specificity, because one of the trademark activities of Treg cells in vitro is suppressing immune in islet transplantation) is a substantial concern (57,85) that needs to be addressed with appropriate dosage and responses nonspecifically. Furthermore, a cocktail of suppressive cytokine milieu at the local inflammatory duration of its use. As for CTLA4 induction, cyclosporine was reported to be inhibitory (32) , but dexametha-site, contributed by local regulatory and other cells, may even convert Teff cells to antigen-specific Treg cells sone enhanced CTLA4 expression on activated T cells (140). (130), inducing a long-lasting local immune tolerance.
The best example of CTLA4-based immunotherapeu-IMMUNOMODULATION TO ENHANCE tic agent is perhaps CTLA4Ig fusion proteins. The dis-ENDOGENOUS REGULATORY MECHANISMS appointing outcome from trials with CTLA4Ig treatment in islet transplantation in nonhuman primate models Immunoregulatory cell therapy presents an appealing venue in future medicine. However, immunomodulation dampened the initial enthusiasm for the agent (12). However, clinical interest in CTLA4Ig and its deriva-to elicit the potentials of patients' endogenous tolerogenic elements may also be critical for effective induc-tives has been reignited by its recent success in treating chronic inflammatory diseases or reversing late-stage in-tion of immune tolerance. Immunomodulatory agents generally are viewed as necessary "evils" in transplanta-flammatory pathology against allotransplants (1,12,129). The effect of CTLA4Ig on late stage inflammation is tions. Recent evidence, however, suggests that there may be "good" (tolerogenic potential) in the "evil," in surprising because the agent was developed to inhibit the early step of T-cell activation through blocking B7/ that some immunosuppressive agents appear conducive to tolerance induction, whereas others may be counter-CD28 costimulation. Untowardly, despite the long-term research of CTLA4Ig, it is unclear how this agent con-productive to immune tolerance, as indicated by their effect on CTLA4 and Treg cells. For example, low-dose trols inflammatory damage. It also remains uncertain whether it can impede or promote Treg cells (12,109). anti-CD3 have been found to expand Treg cells (18) . Such an effect is consistent with their therapeutic effect.
Evidence strongly suggests that CTLA4Ig may induce IDO expression in innate immune cells including DCs. In newly diabetic NOD mice, low-dose anti-CD3 treatment induced remission of the disease. The finding pro-IDO induction in DCs may deliver a tolerogenic signal to T cells (76). voked clinical trials, using two humanized nonmitogenic anti-CD3 antibodies, which showed that anti-CD3 treat-COORDINATED PATTERNS OF GENE ment restrained the progression of autoimmune attacks EXPRESSION IN ADAPTIVE AND INNATE against β-cells and partially preserved the residual β-cell REGULATORY CIRCUITS AS BIOMARKERS mass in recent-onset diabetic patients. Enhanced immu-FOR TOLERANCE PROGRESSION noregulation was found to be the main mechanism of restored tolerance to β-cells (18) . Antithymocyte globu-One challenge for immune tolerance induction in clinical transplantation is how to measure tolerance pro-lins (ATG), a prototype of lymphodepleting agents, may also have the potentials to expand or induce Treg cells, gression in patients, so the right patients can be weaned off from immunosuppressive drugs at the right times but this effect remains debated and more concrete evidence needs to be provided (14, 33, 99) . Evidence for the with the right tempo. A variety of approaches have been used to test molecular and cellular parameters associated tolerogenic potentials of B-cell depletion therapies has been documented in clinical trials and experimental with responses to grafts (27, 84, 126) , but reliable assays have yet to be presented for clinical utility. Encourag-studies with animal models (53,69). The exact mechanism of Treg cell expansion and induction in vivo by ingly, key molecules of immunoregulation may be useful as biomarkers for immune tolerance induction. For immunomodulation remains to be elucidated. It might even implicate cells in the nonhematopoietic lineage. In-example, FOXP3 mRNA levels in urine predicted the reversibility of acute renal graft rejection (82) , and high deed, bone marrow mesenchymal stem cells have been shown to suppress immune cells in various settings (63) . levels of FOXP3 mRNA existed in tolerized kidney grafts (60) . Likewise, clinical evidence suggests that en-Their immunomodulatory role could be partially mediated by Treg cell induction (106) .
hanced CTLA4 expression may predicate immune tolerance in humans. A natural example is presented from Some conventional immunosuppressive agents, including calcineurin inhibitors and cyclophosphamide, the studies of HIV immunity. Kaufmann et al. found that CTLA4 upregulation by CD4 + T cells in HIV-infected were shown to be deleterious to Treg cells (15, 105) . On the other hand, rapamycin, a routinely used immunosup-patients correlates with persistence of the virus; conversely, lower CTLA4 expression by T cells correlates pressive drug in transplantations, was found to expand Treg cells (7) , making it an appealing choice of agent in with effective viral elimination (59). This example, to-gether with immune damages associated with subtle the ability of insulin-producing cells to replicate and replenish themselves in the long term, or was ineffective CTLA4 reductions dictated by genetic polymorphism (46, 66, 132, 137) , suggests that quantitative variations of to control the chronic immune response, or a combination of the two. Although the enthusiasm for the field CTLA4 may serve as indicators of immune tolerance progression in humans.
appears dampened by these challenges, islet transplantation has been proven to be a clinically viable remedy Another challenge in the clinical settings is that peripheral blood is currently the practical access to gauge for severe cases of T1DM that cannot be controlled by intensive insulin therapy without increasing the risk for the function of immune cells. Analyses of blood samples may not always reflect disease activity in a specific or-severe hypoglycemic episodes (96) .
Regardless of the recent set-backs in islet transplanta-gan. However, a status of transplant immunity may be revealed in circulating immune cells with a specific pat-tion, clinical experience with this approach and other areas of transplantation have indeed generated promis-tern of gene regulation. For example, elevation of mRNA levels for cytotoxic lymphocyte genes predicted ing leads, as significant improvement in long-term results reported in recent clinical trials, with a small frac-islet graft rejection in human patients (50) .
Given the well-documented roles of CTLA4 and tion of transplant recipients who was able to maintain long-term graft function even after discontinuation of Foxp3 in immunoregulation, their expression is expected to serve as indicators for tolerance induction. Potential immunosuppressive treatment ("operational tolerance") (8, 9, 31, 78, 126) . Therefore, even though evolution may relationships may exist between CTLA4 and Foxp3 levels and expression of genes associated with innate sup-have shaped robust and multiple layers of mechanisms in the immune system to reject "foreign" antigenic sub-pressors, such as arginase I, iNOS, and IDO. A dynamic relationship between the two branches may suggest ef-stances, which prevent the selective acceptance of harmless allografts, the induction of transplant tolerance in fective control of pathogenic T-cell responses, manifested in suppressed expression of cytotoxic genes such humans is indeed an objective within reach. However, "reeducating" the immune system to accept a "foreign" as IFN-γ, granzyme b, and perforin. With the premise that immune tolerance induction requires integrated transplant may require understanding and successful manipulation of a number of selected immune tolerance functioning by both innate and adaptive regulatory cells, coordinated patterns of gene expressions in adaptive and pathways, with integration and synergy of innate and adaptive immunoregulatory functions that could require innate regulatory circuits may be prognostic of immune tolerance progression. cellular and molecular manipulation of the microenvironment at the transplant site. 
